NASDAQ: CAPRCapricor Therapeutics Inc Stock
$35.04+0.32 (+0.92%)
Updated Apr 15, 2026
CAPR Price
$35.04
Fair Value Price
$5.74
Market Cap
$2.02B
52 Week Low
$4.30
52 Week High
$40.37
P/E
-15.5x
P/B
6.59x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$105.04M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.16
Operating Cash Flow
-$70M
Beta
1.07
Next Earnings
May 20, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CAPR Overview
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CAPR's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CAPR
Ranked#332 of 466
Ranked#332 of 466
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.92 | A | |
| $199.33 | A | |
| $6.20 | A |
Be the first to know about important CAPR news, forecast changes, insider trades & much more!
CAPR News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CAPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CAPR ($35.04) is overvalued by 510.19% relative to our estimate of its Fair Value price of $5.74 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CAPR ($35.04) is not significantly undervalued (510.19%) relative to our estimate of its Fair Value price of $5.74 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CAPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CAPR due diligence checks available for Premium users.
Valuation
CAPR fair value
Fair Value of CAPR stock based on Discounted Cash Flow (DCF)
Price
$35.04
Fair Value
$5.74
Overvalued by
510.19%
CAPR ($35.04) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CAPR ($35.04) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CAPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CAPR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-15.5x
Industry
26.54x
Market
30.93x
CAPR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.59x
Industry
5.05x
CAPR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CAPR's financial health
Profit margin
Revenue
$0.0
Net Income
-$30.2M
Profit Margin
0%
CAPR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$355.9M
Liabilities
$50.2M
Debt to equity
0.16
CAPR's short-term assets ($322.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CAPR's short-term assets ($322.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CAPR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CAPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.6M
Investing
$43.1M
Financing
$248.8M
CAPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CAPR vs Biotech Stocks
Capricor Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.